Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
QuintilesIMS
Accenture
Novartis
Chubb
Medtronic
Dow
Colorcon
Cantor Fitzgerald
Julphar

Generated: January 19, 2018

DrugPatentWatch Database Preview

DALVANCE Drug Profile

« Back to Dashboard

Which patents cover Dalvance, and when can generic versions of Dalvance launch?

Dalvance is a drug marketed by Allergan Sales Llc and is included in one NDA. There are four patents protecting this drug.

This drug has fifty-three patent family members in sixteen countries.

The generic ingredient in DALVANCE is dalbavancin hydrochloride. One supplier is listed for this compound. Additional details are available on the dalbavancin hydrochloride profile page.
Summary for DALVANCE
International Patents:53
US Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 5
Clinical Trials: 2
Patent Applications: 1
Drug Prices:see details
DailyMed Link:DALVANCE at DailyMed
Drug patent expirations by year for DALVANCE
Pharmacology for DALVANCE

US Patents and Regulatory Information for DALVANCE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Sales Llc DALVANCE dalbavancin hydrochloride POWDER;IV (INFUSION) 021883-001 May 23, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Allergan Sales Llc DALVANCE dalbavancin hydrochloride POWDER;IV (INFUSION) 021883-001 May 23, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan Sales Llc DALVANCE dalbavancin hydrochloride POWDER;IV (INFUSION) 021883-001 May 23, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan Sales Llc DALVANCE dalbavancin hydrochloride POWDER;IV (INFUSION) 021883-001 May 23, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Allergan Sales Llc DALVANCE dalbavancin hydrochloride POWDER;IV (INFUSION) 021883-001 May 23, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan Sales Llc DALVANCE dalbavancin hydrochloride POWDER;IV (INFUSION) 021883-001 May 23, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan Sales Llc DALVANCE dalbavancin hydrochloride POWDER;IV (INFUSION) 021883-001 May 23, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for DALVANCE

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
AstraZeneca
Novartis
Chubb
McKesson
Merck
Teva
Fish and Richardson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot